Aligos selects Stephen Harrison as principal investigator in ALG-055009 study

Aligos Therapeutics announced the selection of Stephen Harrison, MD as principal investigator of, and key design elements for, its upcoming Ph2a study of NASH drug candidate ALG-055009. The company has now completed Phase 1 testing, where single oral less than or equal to4 mg doses and 14 daily less than or equal to1.0 mg doses of ALG-055009 were found to be well tolerated with linear PK, low variability and expected effects on biomarkers, including generally dose responsive reductions in various atherogenic lipids and increases in sex hormone binding globulin, a marker of target engagement.